ArticleBMC neurology2025

Favorable responses to upadacitinib, a JAK1 inhibitor, in long COVID patients with predominant neuropsychiatric symptoms: case reports in 2 autistic patients and one typically developing patient.

Harumi Jyonouchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.